Xvivo Perfusion Ab Stock Key Fundamental Indicators
| XVIPYDelisted Stock | USD 5.70 0.53 8.51% |
As of the 13th of February 2026, Xvivo Perfusion maintains the Standard Deviation of 4.64, market risk adjusted performance of (1.09), and Mean Deviation of 2.17. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xvivo Perfusion AB, as well as the relationship between them.
Xvivo Perfusion's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Xvivo Perfusion's valuation are provided below:Xvivo Perfusion AB does not presently have any fundamental gauges for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Xvivo |
Search Suggestions
| X | United States Steel | CompanyDelisted |
| XP | Xp Inc | Company |
| XELAP | Exela Technologies Preferred | Company |
| XDFPX | Flaherty Crumrine Dynamic | Mutual Fund |
| XB | BondBloxx ETF Trust | ETF |
| XNG | ARCA Natural Gas | Index |
| XT | XT Token | Cryptocurrency |
| X10001AB5 | ALVGR 32 | Corporate Bond |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Xvivo Perfusion AB has a Debt To Equity of 0.004%. This is much higher than that of the sector and significantly higher than that of the Debt To Equity industry. The debt to equity for all United States stocks is notably lower than that of the firm.
Xvivo Perfusion AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xvivo Perfusion's current stock value. Our valuation model uses many indicators to compare Xvivo Perfusion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xvivo Perfusion competition to find correlations between indicators driving Xvivo Perfusion's intrinsic value. More Info.Xvivo Perfusion AB is rated second in return on equity category among its peers. It is rated third in return on asset category among its peers reporting about 0.24 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Xvivo Perfusion AB is roughly 4.10 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Xvivo Perfusion by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Xvivo Perfusion's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Xvivo Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xvivo Perfusion's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Xvivo Perfusion could also be used in its relative valuation, which is a method of valuing Xvivo Perfusion by comparing valuation metrics of similar companies.Xvivo Perfusion is currently under evaluation in debt to equity category among its peers.
Xvivo Fundamentals
| Return On Equity | 0.025 | |||
| Return On Asset | 0.0061 | |||
| Profit Margin | 0.08 % | |||
| Gross Profit | 188.28 M | |||
| Net Income | 8.15 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.48 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Number Of Employees | 118 | |||
| Beta | 1.92 |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Xvivo Pink Sheet
If you are still planning to invest in Xvivo Perfusion AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Xvivo Perfusion's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |